English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Rosiglitazone is a thiazolidinedione derivative oral hypoglycemic agent active in both diabetic animal models and type 2 diabetic patients. Rosiglitazone is a high affinity ligand for the peroxisome proliferator-activated receptor gamma, which is responsible for the insulin-sensitizing action of the compound. Recent large clinical trials found an association between the antidiabetic drug rosiglitazone therapy and increased risk of cardiovascular adverse events.

bmc pharmacology

Electrophysiological effects of rosiglitazone on heart ventricular papillary muscles of control and diabetic histidine decarboxylase knock-out and wild-type mice